US equities |
META $642.62 ▲+0.00% MU $877.55 ▲+0.00% TSLA $372.22 ▲+0.00% SPCX $147.49 ▲+0.00% NU $15.16 ▲+0.00% NVDA $210.96 ▲+0.00% SNDK $1,238.03 ▲+0.00% NBIS $158.74 ▲+0.00%
FinancialContent

Articles published by Pyxis Oncology

News headline image
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Announces Proposed Public Offering
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Participate in Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Participate in Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Participate in Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Participate in September Investor and Industry Conferences
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS
News headline image
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
From Pyxis Oncology
Via GlobeNewswire
Tickers PYXS